Evidence map›Paper›PMID 25419628›Full record

ArticleNature immunology2015

The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection.

Christopher Schliehe, Elizabeth K Flynn, Bojan Vilagos, Udochuku Richson, Savitha Swaminanthan, Berislav Bosnjak, Lisa Bauer, Richard K Kandasamy, Isabel M Griesshammer, Lindsay Kosack and 17 more

Open access · greenAbstract read
In one paragraph

Article in Nature immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.

  1. Influenza and tuberculosis co-infection: A systematic review.Influenza and other respiratory viruses · 2020
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. The Roles of H3K9me3 Writers, Readers, and Erasers in Cancer Immunotherapy.International journal of molecular sciences · 2024
    Review
  18. Article
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 7 institutions in 4 countries.

Christopher SchlieheCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Elizabeth K Flynn *Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Bojan Vilagos *CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Udochuku Richson *CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Savitha SwaminanthanSeattle Biomedical Research Institute, Seattle, WA, USA.
Berislav BosnjakDepartment of Dermatology, DIAID, Experimental Allergy, Medical University of Vienna, Vienna, Austria.
Lisa BauerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Richard K KandasamyCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Isabel M GriesshammerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Lindsay KosackCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Frank SchmitzSeattle Biomedical Research Institute, Seattle, WA, USA.
Vladimir LitvakUniversity of Massachusetts, Worcester, MA, USA.
James SissonsSeattle Biomedical Research Institute, Seattle, WA, USA.
Alexander LercherCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Anannya BhattacharyaCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Kseniya KhaminaCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Anna L TrivettCenter for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Lino TessarolloCenter for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Ildiko MesteriDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Anastasiya HladikCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Doron MerklerDepartment of Pathology and Immunology, Division of Clinical Pathology, University & University Hospital of Geneva, Geneva, Switzerland.
Stefan KubicekCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Sylvia KnappCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Michelle M EpsteinDepartment of Dermatology, DIAID, Experimental Allergy, Medical University of Vienna, Vienna, Austria.
David E Symer *Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Alan Aderem *Seattle Biomedical Research Institute, Seattle, WA, USA.
Andreas BergthalerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Austrian Academy of Sciences · ATCenter for Infectious Disease Research · USFrederick National Laboratory for Cancer Research · USMedical University of Vienna · ATNational Cancer Institute · USUniversity Hospital of Geneva · CHUniversity of Massachusetts Chan Medical School · US

Funding

Systems Biology CoreU19AI100627 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ULEVITCH, RICHARD J · 2012 to 2021
$49.1M
LPS Signaling in Macrophages: The Roll of TollR01AI032972 · NIAID · UNIVERSITY OF WASHINGTON · PI ADEREM, ALAN A · 1992 to 2020
$14.6M
Gene Targeting FacilityZICBC011265 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TESSAROLLO, LINO · 2010 to 2025
$8.9M
LPS REGULATION OF MACROPHAGE FUNCTIONR01AI025032 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI ADEREM, ALAN A · 1987 to 2016
$6.7M
Austrian Science Fund FWF P 25360NIAID NIH HHS R01 AI025032NIAID NIH HHS R01AI025032NIAID NIH HHS R01 AI032972NIAID NIH HHS R01AI032972NIAID NIH HHS U19 AI100627NIAID NIH HHS U19AI100627
6 · The paper itself

Abstract

Immune responses are tightly regulated to ensure efficient pathogen clearance while avoiding tissue damage. Here we report that Setdb2 was the only protein lysine methyltransferase induced during infection with influenza virus. Setdb2 expression depended on signaling via type I interferons, and Setdb2 repressed expression of the gene encoding the neutrophil attractant CXCL1 and other genes that are targets of the transcription factor NF-κB. This coincided with occupancy by Setdb2 at the Cxcl1 promoter, which in the absence of Setdb2 displayed diminished trimethylation of histone H3 Lys9 (H3K9me3). Mice with a hypomorphic gene-trap construct of Setdb2 exhibited increased infiltration of neutrophils during sterile lung inflammation and were less sensitive to bacterial superinfection after infection with influenza virus. This suggested that a Setdb2-mediated regulatory crosstalk between the type I interferons and NF-κB pathways represents an important mechanism for virus-induced susceptibility to bacterial superinfection.

Indexed as

AnimalsChemokine CXCL1Disease SusceptibilityFemaleHistone-Lysine N-MethyltransferaseInterferon Type IMaleMice, Inbred C57BLMice, KnockoutNF-kappa BOligonucleotide Array Sequence AnalysisOrthomyxoviridaeOrthomyxoviridae InfectionsPneumoniaReal-Time Polymerase Chain ReactionRNAChemokine CXCL1Cxcl1 protein, mouseHistone-Lysine N-MethyltransferaseInterferon Type INF-kappa BRNA

Identifiers

PMID25419628
PMCPMC4320687
OpenAlexW2071296698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.